Zoetis Stock Reaches Lowest P/E Ratio in Its History Amid Controversy
Zoetis (ZTS) is trading at its lowest price-to-earnings (P/E) ratio ever, currently at 19 times earnings, due to controversy surrounding its osteoarthritis pain treatment for dogs, Librela. Despite the setback, the company has a strong pipeline and growth potential, making it an attractive investment opportunity for patient investors.
Tickers: $ZTS
Topics: animal healthcare Librela regulatory issues stock performance Zoetis